GlassScriptPhysician profile
Kristopher Atzeff
NPI 1073577045
$1,564.52
in general payments reported to CMS, 2019-2025
30 companies · $39.12 in 2025
The $39.12 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $185 · 2021: $239 · 2022: $273 · 2023: $402 · 2024: $257 · 2025: $39.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $698.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $284.22 | 2019-2023 | Lupron Depot |
| Boston Scientific Corporation | $221.83 | 2020-2024 | Rezum Generator, Spaceoar Vue System - 10ml |
| Antares Pharma, INC. | $172.89 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Olympus America INC. | $149.18 | 2020-2024 | Itind System, Soltive, Olympus |
| Dendreon Pharmaceuticals LLC | $87.91 | 2020-2023 | Provenge |
| Pfizer INC. | $72.44 | 2019 | |
| Astellas Pharma US INC | $62.41 | 2021 | |
| Coloplast Corp | $49.68 | 2024 | |
| Amgen INC. | $46.31 | 2019-2020 | |
| Clarus Therapeutics INC. | $36.46 | 2021 | |
| Verity Pharmaceuticals INC. | $35.47 | 2023-2024 | Trelstar |
| Halozyme INC | $34.19 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $26.48 | 2022 | |
| Myriad Genetic Laboratories, INC. | $26.40 | 2022 | |
| Calyxo, INC. | $25.66 | 2024 | Cvac Aspiration System |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.72 | 2024 | Proclaim |
| Axonics, INC. | $23.82 | 2023 | Axonics |
| Avation Medical, INC. | $23.44 | 2025 | Vivally System |
| Travere Therapeutics, INC. | $21.28 | 2021 | |
| Merck Sharp & Dohme LLC | $18.33 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $18.25 | 2021 | |
| Allergan, INC. | $17.56 | 2021 | |
| Neotract INC. | $16.08 | 2019 | |
| Sumitomo Pharma America, INC. | $15.68 | 2025 | Gemtesa |
| Mission Pharmacal Company | $14.62 | 2023 | Uribel |
| Dentsply Ih INC. | $13.96 | 2019 | |
| Hollister Incorporated | $13.36 | 2021 | |
| Karl Storz Endoscopy-America | $11.89 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,124.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristopher Atzeff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.